Reply to the letter by Gaetano Loscocco, Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19

被引:0
作者
Akiyoshi Takami
机构
[1] Aichi Medical University School of Medicine,Division of Hematology, Department of Internal Medicine
来源
International Journal of Hematology | 2020年 / 112卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:127 / 127
相关论文
共 33 条
[1]  
Takami A(2020)Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19 Int J Hematol 395 1033-1034
[2]  
Mehta P(2020)COVID-19: consider cytokine storm syndromes and immunosuppression Lancet 80 607-613
[3]  
McAuley DF(2020)SARS-CoV-2 infection associated hemophagocytic lymphohistiocytosis: an autopsy series with clinical and laboratory correlation medRxiv 395 497-506
[4]  
Brown M(2020)Tocilizumab for hemophagocytic syndrome in a kidney transplant recipient with COVID-19 Ann Intern Med undefined undefined-undefined
[5]  
Sanchez E(2020)Favorable anakinra responses in severe Covid-19 patients with secondary hemophagocytic lymphohistiocytosis Cell Host Microbe undefined undefined-undefined
[6]  
Tattersall RS(2020)The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19 J Infect undefined undefined-undefined
[7]  
Manson JJ(2020)Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet undefined undefined-undefined
[8]  
Prilutskiy A(undefined)undefined undefined undefined undefined-undefined
[9]  
Kritselis M(undefined)undefined undefined undefined undefined-undefined
[10]  
Shevtsov A(undefined)undefined undefined undefined undefined-undefined